Portal de Periódicos da CAPES

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology

2016; American Medical Association; Volume: 140; Issue: 12 Linguagem: Inglês

10.5858/arpa.2016-0331-cp

1543-2165

Angela N. Bartley, M. Kay Washington, Christina B. Ventura, Nofisat Ismaila, Carol Colasacco, Al B. Benson, Alfredo Carrato, Margaret L. Gulley, Dhanpat Jain, Sanjay Kakar, Helen Mackay, Catherine Streutker, Laura H. Tang, Megan L. Troxell, Jaffer A. Ajani,

Gastrointestinal Tumor Research and Treatment

- ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA.